Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

被引：62

作者：

Gudmundsdotter, Lindvi ^{[1
,2
]}

Nilsson, Charlotta ^{[1
,2
]}

Brave, Andreas ^{[1
,2
]}

Hejdeman, Bo ^{[3
]}

Earl, Patricia ^{[4
]}

Moss, Bernard ^{[4
]}

Robb, Merlin ^{[5
]}

Cox, Josephine ^{[6
]}

Michael, Nelson ^{[5
]}

Marovich, Mary ^{[5
]}

Biberfeld, Gunnel ^{[1
,2
]}

Sandstrom, Eric ^{[3
]}

Wahren, Britta ^{[1
,2
]}

机构：

[1] Swedish Inst Infect Dis Control, Stockholm, Sweden

[2] Karolinska Inst, Stockholm, Sweden

[3] Soder Sjukhuset, Stockholm, Sweden

[4] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA

[5] Walter Reed Army Inst Res, Dept Retroviral, Rockville, MD USA

[6] IAVI, New York, NY USA

来源：

VACCINE | 2009年 / 27卷 / 33期

基金：

美国国家卫生研究院; 瑞典研究理事会;

关键词：

HIV-1; vaccine; Modified Vaccinia virus Ankara (MVA); Pre-existing immunity; CD8(+) T-CELL; VIRUS ANKARA; VACCINATION; VECTOR; IMMUNOGENICITY; IMMUNIZATION; SMALLPOX; PROTEIN; SAFETY; GLYCOPROTEIN;

D O I：

10.1016/j.vaccine.2009.05.018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The presence of vector-specific immune responses may hamper the induction of responses to a foreign antigen encoded by the vector. We evaluated the impact of pre-existing immunity to vaccinia virus on the induction of HIV-specific responses after immunization of healthy volunteers with a HIV-1 DNA prime-MVA boost vaccine. Following three priming immunizations with HIV-1 DNA plasmids, the volunteers were boosted with a single injection of recombinant MVA encoding HIV-1 proteins. Pre-existing immunity to vaccinia virus did not reduce the proportion of individuals who responded to HIV-1, but: did lower the magnitude of responses. Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：4468 / 4474

页数：7

共 33 条

[1]

AMARA RR, 2008, KEYSTONE S HIV VACCI

[2] Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity [J].

Belyakov, IM ;

Moss, B ;

Strober, W ;

Berzofsky, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4512-4517

[3] Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].

Blanchard, TJ ;

Alcamí, A ;

Andrea, P ;

Smith, GL .

JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167

[4] A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8+ T-cell and humoral responses in mice [J].

Brave, Andreas ;

Boberg, Andreas ;

Gudmundsdotter, Lindvi ;

Rollman, Erik ;

Hallermalm, Kristian ;

Ljungberg, Karl ;

Blomberg, Pontus ;

Stout, Richard ;

Paulie, Staffan ;

Sandstrom, Eric ;

Biberfeld, Gunnel ;

Earl, Patricia ;

Moss, Bernard ;

Cox, Josephine H. ;

Wahren, Britta .

MOLECULAR THERAPY, 2007, 15 (09) :1724-1733

[5] SAFETY OF AND IMMUNOLOGICAL RESPONSE TO A RECOMBINANT VACCINIA VIRUS-VACCINE EXPRESSING HIV ENVELOPE GLYCOPROTEIN [J].

COONEY, EL ;

COLLIER, AC ;

GREENBERG, PD ;

COOMBS, RW ;

ZARLING, J ;

ARDITTI, DE ;

HOFFMAN, MC ;

HU, SL ;

COREY, L .

LANCET, 1991, 337 (8741) :567-572

[6] Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus [J].

Cosma, A ;

Bühler, S ;

Nagaraj, R ;

Staib, C ;

Hammarin, AL ;

Wahren, B ;

Goebel, FD ;

Erfle, V ;

Sutter, G .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (02) :406-410

[7] HUMORAL IMMUNE-RESPONSE ELICITED BY HIGHLY ATTENUATED VARIANTS OF VACCINIA VIRUS AND BY AN ATTENUATED RECOMBINANT EXPRESSING HIV-1 ENVELOPE PROTEIN [J].

DALLO, S ;

MAA, JS ;

RODRIGUEZ, JR ;

RODRIGUEZ, D ;

ESTEBAN, M .

VIROLOGY, 1989, 173 (01) :323-329

[8] A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge [J].

Dunachie, S. J. ;

Walther, M. ;

Epstein, J. E. ;

Keating, S. . ;

Berthoud, T. ;

Andrews, L. ;

Andersen, R. F. ;

Bejon, P. ;

Goonetilleke, N. ;

Poulton, I. ;

Webster, D. P. ;

Butcher, G. ;

Watkins, K. ;

Sinden, R. E. ;

Levine, G. L. ;

Richie, T. L. ;

Schneider, J. ;

Kaslow, D. ;

Gilbert, S. C. ;

Carucci, D. J. ;

Hill, A. V. S. .

INFECTION AND IMMUNITY, 2006, 74 (10) :5933-5942

[9] SUCCESSFUL VACCINATION WITH A POLYVALENT LIVE VECTOR DESPITE EXISTING IMMUNITY TO AN EXPRESSED ANTIGEN [J].

FLEXNER, C ;

MURPHY, BR ;

ROONEY, JF ;

WOHLENBERG, C ;

YUFEROV, V ;

NOTKINS, AL ;

MOSS, B .

NATURE, 1988, 335 (6187) :259-262

[10] Duration of antiviral immunity after smallpox vaccination [J].

Hammarlund, E ;

Lewis, MW ;

Hansen, SG ;

Strelow, LI ;

Nelson, JA ;

Sexton, GJ ;

Hanifin, JM ;

Slifka, MK .

NATURE MEDICINE, 2003, 9 (09) :1131-1137

← 1 2 3 4 →